3:43 PM
 | 
Jun 08, 2017
 |  BC Innovations  |  Translation in Brief

TGFβ on the brain

Why Stanford, SRI are boosting TFGβ signaling to treat Parkinson’s

Against a checkered past of TGFβ signaling in preclinical models of Parkinson’s disease, a Stanford University team has provided new evidence that stimulating the pathway holds promise in the indication. Stanford and SRI International have made a small molecule activator of the pathway and are looking for a partner to help develop it in PD and other neurological indications.

In vitro and in vivo studies of the role of transforming growth factor β (TGFβ) signaling in PD have produced contradictory results. While TGFβ ligands protected dopaminergic neurons in cell culture models of the disease, intracranial administration or overexpression in animal models has either been ineffective or worsened neuronal loss.

In a Journal of Neuroscience study in April, a Stanford team led by Jian Luo and Tony Wyss-Coray addressed two problems with the previous in vivo studies by creating mice in which...

Read the full 691 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >